First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis
Objective The objective of this study was to evaluate the cost-effectiveness of durvalumab in combination with chemotherapy compared with chemotherapy alone as first-line therapy for metastatic non-small-cell lung cancer (NSCLC) from the perspective of the US payer.Methods Based on the POSEIDON clin...
Main Authors: | Ling Fang, Zhiwei Zheng, Hongfu Cai |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-12-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/12/e076383.full |
Similar Items
-
First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
by: Wenjie Liu, et al.
Published: (2023-07-01) -
First-line nivolumab plus ipilimumab or chemotherapy chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
by: Xueqiong Cao, et al.
Published: (2022-09-01) -
Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
by: Zhiwei Zheng, et al.
Published: (2023-09-01) -
Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
by: Lulu Liu, et al.
Published: (2023-01-01) -
Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
by: Zhuo-miao Ye, et al.
Published: (2023-02-01)